{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:27:07Z","timestamp":1783344427655,"version":"3.54.6"},"reference-count":32,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,4]],"date-time":"2023-04-04T00:00:00Z","timestamp":1680566400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020124","name":"Seagen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020124","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.clml.2023.03.015","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T21:37:44Z","timestamp":1680125864000},"page":"527-534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States"],"prefix":"10.1016","volume":"23","author":[{"given":"Allison","family":"Winter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2468-9482","authenticated-orcid":false,"given":"Nicholas","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Surinach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Fanale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina S.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Narkhede","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2023.03.015_bib0001","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1200\/JCO.2013.53.1194","article-title":"Treatment of Hodgkin lymphoma: a 50-year perspective","volume":"32","author":"Canellos","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.015_bib0002","doi-asserted-by":"crossref","DOI":"10.1177\/2040620720902911","article-title":"Optimizing outcomes in relapsed\/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies","volume":"11","author":"Vassilakopoulos","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2023.03.015_bib0003","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/ncponc1186","article-title":"Treatment of Hodgkin lymphoma: the past, present, and future","volume":"5","author":"Evens","year":"2008","journal-title":"Nat Clin Pract Oncol"},{"key":"10.1016\/j.clml.2023.03.015_bib0004","unstructured":"American Society of Hematology. The cure of Hodgkin lymphoma. 2008. Accessed: December 20, 2022. Available at: https:\/\/www.hematology.org\/about\/history\/50-years\/cure-of-hodgkin-lymphoma."},{"key":"10.1016\/j.clml.2023.03.015_bib0005","first-page":"1","article-title":"Managing risk in Hodgkin lymphoma","volume":"13","author":"Armitage","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.clml.2023.03.015_bib0006","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa1510093","article-title":"Adapted treatment guided by interim PET-CT scan in advanced Hodgkin's lymphoma","volume":"374","author":"Johnson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.03.015_bib0007","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/S0140-6736(17)32134-7","article-title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group","volume":"390","author":"Borchmann","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2023.03.015_bib0008","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/S1470-2045(18)30784-8","article-title":"PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study","volume":"20","author":"Casasnovas","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2023.03.015_bib0009","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 Trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2023.03.015_bib0010","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(21)00101-0","article-title":"PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial","volume":"8","author":"Kreissl","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2023.03.015_bib0011","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1182\/bloodadvances.2021005150","article-title":"Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial","volume":"5","author":"Ricardi","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2023.03.015_bib0012","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.015_bib0013","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1182\/blood-2021-151143","article-title":"Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): observations of physicians on treatment and interim PET-adapted regimens","volume":"138","author":"Parsons","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.015_bib0014","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood-2020-140534","article-title":"Real-world characteristics of patients with classical Hodgkin lymphoma receiving frontline brentuximab vedotin with chemotherapy: a retrospective analysis with propensity score matching","volume":"136","author":"Phillips","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.015_bib0015","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1182\/blood-2020-140698","article-title":"Real-world adherence to National Comprehensive Cancer Network (NCCN) guidelines regarding the usage of PET\/CT and reported Deauville scores in advanced stage classical Hodgkin lymphoma: a community oncology practice perspective","volume":"136","author":"Yasenchak","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.015_bib0016","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin's lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.03.015_bib0017","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1177\/1932296819832653","article-title":"The expanding role of real-world evidence trials in health care decision making","volume":"14","author":"Klonoff","year":"2020","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.clml.2023.03.015_bib0018","unstructured":"Birnbaum B, Nussbaum N, Seidl-Rathkopf K, et\u00a0al. Model-assisted cohort selection with bias analysis for generating large-scale cohorts from the EHR for oncology research. CoRR. 2020. Accessed: December 20, 2022. Available at: https:\/\/arxiv.org\/abs\/2001.09765."},{"key":"10.1016\/j.clml.2023.03.015_bib0019","unstructured":"Centers for Disease Control and Prevention. National Program of Cancer Registries (NPCR). 2020. Accessed: December 8, 2022. Available at: https:\/\/www.cdc.gov\/cancer\/npcr\/index.htm."},{"key":"10.1016\/j.clml.2023.03.015_bib0020","article-title":"Comparison of population characteristics in real-world clinical oncology databases in the US: Flatiron Health, SEER and NPCR","author":"Xinran","year":"2020","journal-title":"medRXiv"},{"key":"10.1016\/j.clml.2023.03.015_bib0021","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s12874-017-0436-z","article-title":"New methods for estimating follow-up rates in cohort studies","volume":"17","author":"Xue","year":"2017","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clml.2023.03.015_bib0022","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2023.03.015_bib0023","unstructured":"NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Hodgkin Lymphoma (version 2.2023). 2022. Accessed: December 20, 2022. Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf."},{"key":"10.1016\/j.clml.2023.03.015_bib0024","doi-asserted-by":"crossref","first-page":"322","DOI":"10.6004\/jnccn.2022.0021","article-title":"NCCN Guidelines\u00ae Insights: Hodgkin Lymphoma, Version 2.2022","volume":"20","author":"Hoppe","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.clml.2023.03.015_bib0025","doi-asserted-by":"crossref","first-page":"e435","DOI":"10.1016\/j.clml.2021.12.012","article-title":"Outcomes among classical Hodgkin lymphoma patients after an interim PET scan: a real-world experience","volume":"22","author":"Hamid","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2023.03.015_bib0026","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hon.2437_53","article-title":"Response-adjusted therapy for advanced Hodgkin lymphoma (RATHL) trial: longer follow up confirms efficacy of de-escalation after negative interim PET scan","volume":"35","author":"Trotman","year":"2017","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2023.03.015_bib0027","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.3390\/ijerph17051783","article-title":"Resources-stratified guidelines for classical Hodgkin lymphoma","volume":"17","author":"Relecom","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.clml.2023.03.015_bib0028","series-title":"Presented at: Pan Pacific Lymphoma Conference","article-title":"Classic Hodgkin Lymphoma: Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): observations of physicians on treatment and interim PET-adapted regimens","author":"Parsons","year":"2022"},{"key":"10.1016\/j.clml.2023.03.015_bib0029","doi-asserted-by":"crossref","first-page":"629","DOI":"10.2147\/CEOR.S178649","article-title":"Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure","volume":"10","author":"Bonafede","year":"2018","journal-title":"Clinicoecon Outcomes Res"},{"key":"10.1016\/j.clml.2023.03.015_bib0030","first-page":"2453","article-title":"Patient-reported distress in Hodgkin lymphoma across the survivorship continuum","volume":"27","author":"Troy","year":"2019","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clml.2023.03.015_bib0031","doi-asserted-by":"crossref","first-page":"10798","DOI":"10.1182\/blood-2022-162603","article-title":"Economic burden of hematopoietic cell transplantation (HCT) among commercially insured patients with hematological malignancies in the United States (US)","volume":"140","author":"Narkhede","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.clml.2023.03.015_bib0032","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1200\/JCO.2015.65.4194","article-title":"Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia","volume":"34","author":"Hapgood","year":"2016","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502300112X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226502300112X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:42:19Z","timestamp":1761871339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226502300112X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S215226502300112X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2023.03.015","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Patient Characteristics, Treatment Patterns, and Outcomes for Patients With Stage III or IV Classic Hodgkin Lymphoma Treated With Frontline ABVD: A Retrospective Database Review in the United States","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2023.03.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}